STIM

Neuronetics Inc. (STIM) | Rumor.io

Neuronetics

STIM

Attention (50-day avg)0%

Attention rank (50-day avg)#1,462

Bullish sentiment (50-day avg)79%

Price to earnings ratio-4.32

Market capitalization194.7M

Earnings per share-0.43

Dividend yield (TTM)—

Revenue (annual)149.2M

Net income (annual)-39.1M

Social

What share of all stock conversation is about STIM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 13

Neuronetics, Inc.'s ER has shown significant growth potential, with the company potentially becoming a billion-dollar company when fully integrated.
The stock's price target is predicted to be $20-30, with some analysts anticipating a price increase to $5.
A significant break above $3.40 is expected to signal the end for short sellers, with the stock potentially continuing its upward momentum.

Generated by AI

Sentiment

Of the messages about STIM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% new	80.17% +1.67	79.04% -15.13
Bearish	—	0% -100	19.83% -1.67	20.96% +15.13

Bullish· Aug 11

$STIM has already demonstrated its earnings potential, achieving profitability in the quarter against expectations of a significant loss.
The stock's price action is strong, with a significant move up, and the company's critical role in the psychedelics rollout and its accelerating business.
$STIM has a cheap valuation and is heavily shorted, but its major investors, including Jorey Chernett, are involved and appear to be winners, which is a positive sign for the stock's future.

Bearish· Jul 19

$STIM has broken crucial support levels, potentially losing momentum.
The stock's price has dropped significantly, with some posts mentioning it falling off a cliff or dying fast.
The company's FDA clearance before earnings was seen as a negative factor, with some traders expressing disappointment in the stock's performance.

Generated by AI

Topics

Of the messages about STIM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	83.56%	64.22%
Technical Analysis	—	—	0%	18.75%
Analysts	—	—	16.44%	5.47%
Earnings	—	—	0%	9.53%
Controversies	—	—	0%	0%
Macro	—	—	0%	2.03%

Analysts· Jul 23

Piper Jaffray initiates coverage of Neuronetics (STIM) with an Overweight rating.
BTIG Research initiates coverage of Neuronetics (STIM) with a Buy rating and a $33 price target.
JMP Securities initiates coverage of Neuronetics (STIM) with an Outperform rating and a $36 price target.

Announcements· Mar 8

Neuronetics, Inc. (STIM) reported record fourth quarter and full year 2022 financial and operating results.
The company's results exceeded expectations, with significant growth in revenue and profitability.
STIM's strong financial performance was driven by the success of its Transcranial Magnetic Stimulation (TMS) products.

Generated by AI

Community

Of the messages about STIM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	68.38%	42.98%
Newcomers	—	0%	31.62%	57.02%

Regulars· Aug 11

$STIM's clinic business is performing well, even before the partnership with $CMPS and the roll-out of psychedelics, with 10% underlying growth and the largest installed base in the US.
Neuronetics has reported a 9.1% increase in total revenue to $41.6 million, with greenbrook revenue up 16.8% and adjusted EBITDA breaking even.
Despite being heavily shorted, $STIM has exceeded expectations on every metric, leading to profitability in the quarter, and is now considered a solid investment opportunity due to its critical role in the psychedelics roll-out and its cheap valuation.

Newcomers· Aug 11

Newcomers are focused on the significant revenue growth of Neuronetics, with Q2 revenue up 9.1% YoY, beating analyst estimates.
The company's operational efficiency improvements are being highlighted, including a $0.3M profit in Adjusted EBITDA and a reduced cash burn to just $1.4M.
There are concerns about Neuronetics' low cash balance, with some users speculating that it may lead to a near-term raise or dilution, potentially impacting the stock price.

Generated by AI

News

Neuronetics Earnings Call: Progress Amid Transition Risks

Detailed price information for Neuronetics Inc (STIM-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Neuronetics Expands CFO Nir Naor’s Financial Leadership Role

Detailed price information for Neuronetics Inc (STIM-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Neuronetics (STIM) Q2 2026 Earnings Call Transcript

Detailed price information for Neuronetics Inc (STIM-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about STIM also mention

#	Name	Attention
1	Brainsway LtdBWAY	0%new
2	AirSculpt Technologies, Inc.AIRS	0%new
3	United Maritime CorporationUSEA	0%0
4	The Oncology Institute Inc.TOI	0%new
5	SCPH - scPharmaceuticals Inc.	——
6	Inotiv Inc.NOTV	0%0
7	DarioHealth Corp.DRIO	0%0
8	Hyperfine, Inc. Class A Common StockHYPR	0%0
9	Biodesix, Inc.BDSX	0%0
10	ClearPoint Neuro Inc.CLPT	0%+0

Neuronetics Inc.

Healthcare
Medical Devices

Neuronetics Inc. is a commercial-stage medical technology company focused on non-invasive neurohealth treatments. Its core offering is the NeuroStar Advanced Therapy System, an office-based transcranial magnetic stimulation platform used primarily for adult patients with major depressive disorder. The company also provides related treatment sessions and support services, serving psychiatric practices and mental health providers in the United States and international markets. Neuronetics operates at the intersection of medical devices and clinic services, combining device commercialization with patient care delivery. Its products are designed to expand access to non-drug therapeutic options for psychiatric and neurological conditions, making the company a significant participant in the neuromodulation market.

Website

Location

3222 Phoenixville Pike

Malvern, PA, 19355

United States

Social

What share of all stock conversation is about STIM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 13

Neuronetics, Inc.'s ER has shown significant growth potential, with the company potentially becoming a billion-dollar company when fully integrated.
The stock's price target is predicted to be $20-30, with some analysts anticipating a price increase to $5.
A significant break above $3.40 is expected to signal the end for short sellers, with the stock potentially continuing its upward momentum.

Generated by AI

Sentiment

Of the messages about STIM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% new	80.17% +1.67	79.04% -15.13
Bearish	—	0% -100	19.83% -1.67	20.96% +15.13

Bullish· Aug 11

$STIM has already demonstrated its earnings potential, achieving profitability in the quarter against expectations of a significant loss.
The stock's price action is strong, with a significant move up, and the company's critical role in the psychedelics rollout and its accelerating business.
$STIM has a cheap valuation and is heavily shorted, but its major investors, including Jorey Chernett, are involved and appear to be winners, which is a positive sign for the stock's future.

Bearish· Jul 19

$STIM has broken crucial support levels, potentially losing momentum.
The stock's price has dropped significantly, with some posts mentioning it falling off a cliff or dying fast.
The company's FDA clearance before earnings was seen as a negative factor, with some traders expressing disappointment in the stock's performance.

Generated by AI

Topics

Of the messages about STIM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	83.56%	64.22%
Technical Analysis	—	—	0%	18.75%
Analysts	—	—	16.44%	5.47%
Earnings	—	—	0%	9.53%
Controversies	—	—	0%	0%
Macro	—	—	0%	2.03%

Analysts· Jul 23

Piper Jaffray initiates coverage of Neuronetics (STIM) with an Overweight rating.
BTIG Research initiates coverage of Neuronetics (STIM) with a Buy rating and a $33 price target.
JMP Securities initiates coverage of Neuronetics (STIM) with an Outperform rating and a $36 price target.

Announcements· Mar 8

Neuronetics, Inc. (STIM) reported record fourth quarter and full year 2022 financial and operating results.
The company's results exceeded expectations, with significant growth in revenue and profitability.
STIM's strong financial performance was driven by the success of its Transcranial Magnetic Stimulation (TMS) products.

Generated by AI

Community

Of the messages about STIM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	68.38%	42.98%
Newcomers	—	0%	31.62%	57.02%

Regulars· Aug 11

$STIM's clinic business is performing well, even before the partnership with $CMPS and the roll-out of psychedelics, with 10% underlying growth and the largest installed base in the US.
Neuronetics has reported a 9.1% increase in total revenue to $41.6 million, with greenbrook revenue up 16.8% and adjusted EBITDA breaking even.
Despite being heavily shorted, $STIM has exceeded expectations on every metric, leading to profitability in the quarter, and is now considered a solid investment opportunity due to its critical role in the psychedelics roll-out and its cheap valuation.

Newcomers· Aug 11

Newcomers are focused on the significant revenue growth of Neuronetics, with Q2 revenue up 9.1% YoY, beating analyst estimates.
The company's operational efficiency improvements are being highlighted, including a $0.3M profit in Adjusted EBITDA and a reduced cash burn to just $1.4M.
There are concerns about Neuronetics' low cash balance, with some users speculating that it may lead to a near-term raise or dilution, potentially impacting the stock price.

Generated by AI

Neuronetics

Social

Aug 13

Bullish· Aug 11

Bearish· Jul 19

Analysts· Jul 23

Announcements· Mar 8

Regulars· Aug 11

Newcomers· Aug 11

Neuronetics a new buy at B Riley on interventional psychiatry platform

Neuronetics stock gains after B.Riley initiates coverage at Buy

B.Riley initiates Neuronetics stock coverage with buy rating

Neuronetics Earnings Call: Progress Amid Transition Risks

Neuronetics Expands CFO Nir Naor’s Financial Leadership Role

Neuronetics (STIM) Q2 2026 Earnings Call Transcript

Also Discussed

Neuronetics Inc.

Company Information

Location

Neuronetics a new buy at B Riley on interventional psychiatry platform

Neuronetics stock gains after B.Riley initiates coverage at Buy

B.Riley initiates Neuronetics stock coverage with buy rating

Neuronetics Earnings Call: Progress Amid Transition Risks

Neuronetics Expands CFO Nir Naor’s Financial Leadership Role

Neuronetics (STIM) Q2 2026 Earnings Call Transcript

Also Discussed

Social

Aug 13

Bullish· Aug 11

Bearish· Jul 19

Analysts· Jul 23

Announcements· Mar 8

Regulars· Aug 11

Newcomers· Aug 11